RA
INBX

Royce & Associates’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Royce & Associates’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12,995
Closed -$494K – 944
2023
Q4 		$494K Buy
+12,995
New +$278K ﹤0.01% 793

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Royce & Associates's INBX Position: Q1 2024 in Review

Royce & Associates sold out of Inhibrx, Inc. Common Stock (INBX) in Q1 2024, closing a stake of 12,995 shares — an estimated $494K sold.

Royce & Associates first reported a position in INBX in Q4 2023 and held it in 1 quarter. The position peaked at $494K in Q4 2023. 126 funds tracked by Wall St. Rank hold INBX as of Q1 2024.

  • Royce & Associates reported no remaining Inhibrx, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Royce & Associates sold 12,995 Inhibrx, Inc. Common Stock shares in Q1 2024, an estimated $494K.
  • Royce & Associates first reported a position in Inhibrx, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • Royce & Associates's Inhibrx, Inc. Common Stock position peaked at $494K in Q4 2023.
  • 126 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q1 2024.

Based on Royce & Associates's 13F filing for Q1 2024, filed 13 May 2024.